Targeting a specific amino acid transporter to treat pancreatic cancer
SLC6A14 as a unique drug target to treat pancreatic cancer
This study is looking at how blocking a specific protein called SLC6A14 can help slow down the growth of pancreatic cancer by cutting off the nutrients the cancer cells need, and it’s for anyone interested in new ways to treat this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Tech University Health Scis Center NIH-funded |
| Lab location | 1 site (Lubbock, United States) |
| Project ID | NIH-11066427 on NIH RePORTER |
What this research studies
This research investigates the role of SLC6A14, an amino acid transporter that is highly active in pancreatic ductal adenocarcinoma (PDAC). The study aims to understand how blocking SLC6A14 can starve cancer cells of essential nutrients, thereby inhibiting their growth. Researchers will use advanced mouse models to explore the effects of SLC6A14 inactivation on cancer progression and survival. Additionally, the research will evaluate the potential of combining SLC6A14 targeting with therapies that enhance nutrient scavenging mechanisms in cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who are seeking innovative treatment options.
Not a fit: Patients with other types of cancer or those who do not have pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that significantly improve survival rates for patients with pancreatic cancer.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, suggesting that this approach may be effective.
Where this research is happening
Lubbock, United States
- Texas Tech University Health Scis Center — Lubbock, United States (Active)
Researchers
- Principal investigator: Bhutia, Yangzom Doma — Texas Tech University Health Scis Center
- Study coordinator: Bhutia, Yangzom Doma
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.